Avutometinib Clinical Trials (2026): 21 Studies for KRAS Activating Mutation & Non Small Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
21 Avutometinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 18 indications (including KRAS Activating Mutation & Non Small Cell Lung Cancer) and 1,486 total planned enrollment. 1 Phase 3 Avutometinib trial and 11 Phase 2 are listed. 12 Avutometinib clinical trials are actively recruiting at 71 U.S. sites across 24 states. Most recent activity: NCT06072781 (Feb 2031).
Where to Participate: All Avutometinib Trial Sites in the U.S. (71 sites across 24 states)
Every actively recruiting Avutometinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | HonorHealth | Phoenix85016 | NCT06072781 | Map |
| AR | University of Arkansas | Little Rock72205 | NCT06072781 | Map |
| CA | UCLA Health | Los Angeles90095 | NCT06072781 | Map |
| CA | UC Davis | Sacramento95817 | NCT06072781 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT06072781 | Map |
| CT | Yale University | New Haven06520 | NCT06072781 | Map |
| FL | Florida Cancer Specialists - South | Fort Myers33901 | NCT06072781 | Map |
| FL | Mount Sinai | Miami Beach33140 | NCT06072781 | Map |
| FL | AdventHealth | Orlando32804 | NCT05512208 | Map |
| FL | AdventHealth | Orlando32804 | NCT06072781 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT06072781 | Map |
| FL | Florida Cancer Specialists Research East | West Palm Beach33401 | NCT06072781 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06495125 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06495125 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT06394804 | Map |
| GA | Winship Cancer Institute at Emory University | Atlanta30322 | NCT06072781 | Map |
| IL | NorthShore University HealthSystem | Evanston60201 | NCT06072781 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06194929 | Map |
| LA | Louisiana State University | New Orleans70112 | NCT06072781 | Map |
| LA | Louisiana State University Medical Center New Orleans | New Orleans70112 | NCT05512208 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore21287 | NCT06072781 | Map |
| MI | Karmanos Cancer Center | Detroit48201 | NCT06072781 | Map |
| MN | Minnesota Oncology Hematology | Minneapolis55404 | NCT06072781 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06072781 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07126158 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT05787561 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06007924 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06394804 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT05787561 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06007924 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06394804 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT05787561 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06007924 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06394804 | Map |
| NM | University of New Mexico Comprehensive Cancer Center | Albuquerque87131 | NCT05512208 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06072781 | Map |
| NY | Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) | Commack11725 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) | Commack11725 | NCT06394804 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06394804 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT06487221 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06072781 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06394804 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Rockville Centre11553 | NCT06007924 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT05787561 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT06394804 | Map |
| NC | Atrium Health | Charlotte28203 | NCT06072781 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT06072781 | Map |
| OH | Ohio State | Hilliard43026 | NCT06072781 | Map |
| OK | Stephenson Cancer Center | Oklahoma City73117 | NCT05512208 | Map |
| OK | University of Oklahoma Medical Center | Oklahoma City73104 | NCT06072781 | Map |
| OR | Willamette Valley Cancer Institute | Eugene97401 | NCT06072781 | Map |
| OR | Northwest Cancer Specialists | Portland97227 | NCT06072781 | Map |
| PA | Asplundh Cancer Pavilion | Jefferson Health | Philadelphia19090 | NCT06072781 | Map |
| PA | Allegheny Health Network | Pittsburgh15224 | NCT06072781 | Map |
| TX | Texas Oncology Central | Austin78731 | NCT06072781 | Map |
| TX | Texas Oncology-Fort Worth Cancer Center | Fort Worth76104 | NCT06072781 | Map |
| TX | Houston Methodist | Houston77030 | NCT06072781 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06072781 | Map |
| TX | MD Anderson Cancer Center | Houston77807 | NCT06369259 | Map |
| TX | Texas Oncology | San Antonio78229 | NCT06072781 | Map |
| TX | Texas Oncology | The Woodlands77380 | NCT06072781 | Map |
| TX | Texas Oncology | Tyler75702 | NCT06072781 | Map |
| UT | Intermountain Medical Center | Murray84107 | NCT06072781 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT06194929 | Map |
| VA | University of Virginia Health System | Charlottesville22908 | NCT06072781 | Map |
| VA | Virginia Cancer Specialists, PC | Gainesville20155 | NCT06072781 | Map |
Avutometinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | suspended | not yet recruiting | Total |
|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | ||||
| P1 | 1 | 1 | 2 | |||
| P1/P2 | 2 | 3 | 1 | 6 | ||
| P2 | 8 | 2 | 1 | 11 | ||
| P3 | 1 | 1 |
Recruiting Avutometinib clinical trials (12)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06072781 | RAMP 301A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | P3 | Low Grade Serous Ovarian Cancer | 270 | Mar 2024 |
| NCT06630260 | 5G-RUBY5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | P1/P2 | Glioblastoma Multiforme (GBM) | 182 | Nov 2024 |
| NCT07318324 | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | P1 | Phase IB | 31 | Jun 2026 |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | P2 | Pancreatic Adenocarcinoma | 36 | Apr 2026 |
| NCT06194929 | DETERMINEDefactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | P1/P2 | Cutaneous Melanoma | 33 | Mar 2024 |
| NCT05512208 | DURAFAKA Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | P2 | Endometrioid Cancer | 55 | Feb 2023 |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | P2 | Advanced Lung Adenocarcinoma | 50 | Jul 2024 |
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | P2 | Gastric Cancer | 27 | Oct 2024 |
| NCT06369259 | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | P2 | Advanced Colorectal Cancer | 33 | Feb 2025 |
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | P2 | Thyroid Cancer | 30 | Aug 2023 |
| NCT06394804 | CHAMELEONA Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | P2 | Low-Grade Serous Ovarian Cancer | 20 | Apr 2024 |
| NCT05787561 | VS-6766A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer | P2 | Mesonephric Gynecologic Cancer | 40 | Mar 2023 |
Avutometinib clinical trials by indication
Non Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05074810 | RAMP203 | P1/P2 | active not recruiting | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients |
| NCT05375994 | RAMP204 | P1/P2 | active not recruiting | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients |
| NCT04620330 | RAMP202 | P2 | completed | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer |
Low Grade Serous Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06072781 | RAMP 301 | P3 | recruiting | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
| NCT06682572 | RAMP201J | P2 | active not recruiting | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients |
Phase IB (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07318324 | — | P1 | not yet recruiting | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer |
Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07126158 | — | P2 | recruiting | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma |
Advanced Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06369259 | — | P2 | recruiting | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer |
Glioblastoma Multiforme (GBM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06630260 | 5G-RUBY | P1/P2 | recruiting | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours |
Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06487221 | — | P2 | recruiting | Avutometinib and Defactinib in Diffuse Gastric Cancer |
Advanced Lung Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06495125 | — | P2 | recruiting | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer |
Low-Grade Serous Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06394804 | CHAMELEON | P2 | recruiting | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer |
Cutaneous Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06194929 | DETERMINE | P1/P2 | recruiting | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma |
Refractory Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06104488 | — | P1 | active not recruiting | A Study of Avutometinib for People With Solid Tumor Cancers |
Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06007924 | — | P2 | recruiting | A Study of Avutometinib and Defactinib in People With Thyroid Cancer |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05798507 | — | Early P1 | active not recruiting | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma |
KRAS Activating Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05669482 | RAMP205 | P1/P2 | active not recruiting | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer |
Mesonephric Gynecologic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05787561 | VS-6766 | P2 | recruiting | A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer |
Endometrioid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05512208 | DURAFAK | P2 | recruiting | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib |
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05200442 | — | P1/P2 | suspended | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer |
Low Grade Ovarian Serous Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04625270 | RAMP 201 | P2 | active not recruiting | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation |
Avutometinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| RAMP 301 | NCT06072781 | P3 | recruiting | Low Grade Serous Ovarian Cancer | 270 | PMID 39375168 |
| DURAFAK | NCT05512208 | P2 | recruiting | Endometrioid Cancer | 55 | — |
| RAMP201J | NCT06682572 | P2 | active not recruiting | Low Grade Serous Ovarian Cancer | 16 | — |
| CHAMELEON | NCT06394804 | P2 | recruiting | Low-Grade Serous Ovarian Cancer | 20 | — |
| VS-6766 | NCT05787561 | P2 | recruiting | Mesonephric Gynecologic Cancer | 40 | — |
| RAMP 201 | NCT04625270 | P2 | active not recruiting | Low Grade Ovarian Serous Adenocarcinoma | 225 | PMID 38493021 |
| RAMP202 | NCT04620330 | P2 | completed | Non Small Cell Lung Cancer | 90 | PMID 35285277 |
Terminated and withdrawn Avutometinib trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05200442suspendedA Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
All Avutometinib trials (21)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06072781 | RAMP 301 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | P3 | recruiting | 270 | Verastem, Inc. | Mar 2024 |
| NCT06630260 | 5G-RUBY | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | P1/P2 | recruiting | 182 | Institute of Cancer Research, United Kingdom | Nov 2024 |
| NCT07318324 | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer | P1 | not yet recruiting | 31 | M.D. Anderson Cancer Center | Jun 2026 | |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | P2 | recruiting | 36 | Washington University School of Medicine | Apr 2026 | |
| NCT06194929 | DETERMINE | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | P1/P2 | recruiting | 33 | University of Utah | Mar 2024 |
| NCT05512208 | DURAFAK | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | P2 | recruiting | 55 | University of Oklahoma | Feb 2023 |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | P1 | active not recruiting | 3 | Memorial Sloan Kettering Cancer Center | Oct 2023 | |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | P2 | recruiting | 50 | Emory University | Jul 2024 | |
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | P2 | recruiting | 27 | Ryan H. Moy, MD, PhD | Oct 2024 | |
| NCT06369259 | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | P2 | recruiting | 33 | M.D. Anderson Cancer Center | Feb 2025 | |
| NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | Early P1 | active not recruiting | 14 | Emory University | Jul 2023 | |
| NCT06682572 | RAMP201J | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | P2 | active not recruiting | 16 | Verastem, Inc. | Oct 2024 |
| NCT05669482 | RAMP205 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | P1/P2 | active not recruiting | 40 | Verastem, Inc. | Mar 2023 |
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | P2 | recruiting | 30 | Memorial Sloan Kettering Cancer Center | Aug 2023 | |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | P1/P2 | suspended | 53 | University of Chicago | Aug 2022 | |
| NCT06394804 | CHAMELEON | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | P2 | recruiting | 20 | Memorial Sloan Kettering Cancer Center | Apr 2024 |
| NCT05074810 | RAMP203 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | P1/P2 | active not recruiting | 153 | Verastem, Inc. | Apr 2022 |
| NCT05787561 | VS-6766 | A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer | P2 | recruiting | 40 | Memorial Sloan Kettering Cancer Center | Mar 2023 |
| NCT04625270 | RAMP 201 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | P2 | active not recruiting | 225 | Verastem, Inc. | Dec 2020 |
| NCT05375994 | RAMP204 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | P1/P2 | active not recruiting | 85 | Verastem, Inc. | Aug 2022 |
| NCT04620330 | RAMP202 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | P2 | completed | 90 | Verastem, Inc. | Dec 2020 |
Avutometinib clinical trials: frequently asked questions
- How many Avutometinib clinical trials are there?
- 21 Avutometinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 11 are actively recruiting participants. 1 is marked completed.
- Are Avutometinib clinical trials recruiting in 2026?
- Yes — 11 Avutometinib trials are actively recruiting in 2026, with 71 U.S. sites across 24 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Avutometinib being studied for?
- Avutometinib is being studied for KRAS Activating Mutation, Non Small Cell Lung Cancer, Ovarian Cancer, Low Grade Serous Ovarian Cancer, Metastatic Cancer and 56 more. The trials are grouped by indication on this page.
- What phase is Avutometinib in?
- Avutometinib clinical trials span 1 Phase 3, 11 Phase 2, 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Avutometinib clinical trials?
- The lead sponsor across the most Avutometinib trials is Verastem, Inc., with 9 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Avutometinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: